Meaning
endocrine-resistant
METASTATIC BREAST CANCER
The trial results found that while alisertib did not restore fulvestrant sensitivity and increase ORRs, promising clinical activity was observed with alisertib monotherapy among patients with endocrine-resistant and cyclin-dependent kinase 4/6 inhibitor–resistant metastatic breast cancer.